NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter

Stock Information for NRX Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics(TM), Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics(TM), Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.